Wilms' tumor or nephroblastoma is a kidney tumor of embryonal origin that occurs in 1 in 10 000 children. A Wilms' tumor suppressor gene, WT1, has been cloned from chromosome 11p13 (Call et al., 1990; Gessler et al., 1990) . The WT1 gene encodes a putative transcription factor with four C 2 H 2 zinc ®ngers at the carboxy terminus and a proline-glutamine rich domain at the amino terminus. The WT1 gene is expressed in developing kidney, gonads and other organs Pritchard-Jones et al., 1990) . The expression during kidney development is ®rst seen at the stage of condensation of the metanephric blastema around the ureteric bud with increasing levels during epithelial dierentiation (Pritchard-Jones et al., 1990; Mundlos et al., 1993) . It is thought that the WT1 gene plays a role in the mesenchymal-epithelial transition possibly by turning o genes involved in maintaining cell proliferation and/or switching on genes involved in dierentiation. The homozygous disruption of WT1 in mice leads to failure of kidney and gonadal development con®rming that this gene is required for urogential development (Kreidberg et al., 1993) .
Through alternative splicing at two sites and two alternative translational start sites, eight dierent protein isoforms can potentially be generated with predicted sizes between 52 and 65 kDa Brenner et al., 1992; Bruening and Pelletier, 1996) . The ®rst alternative splice site (splice I) inserts exon 5 encoding 17 amino acids (WT1+17aa). The second alternative splice site (splice II) alters the spacing between zinc ®nger 3 and 4 by inserting three amino acids (KTS) and altering the target site speci®city of this DNA binding motif (Rauscher et al., 1990; Bickmore et al., 1992) . The transcript containing exon 5 is the most abundant form of WT1 and in a recent detailed study it was shown that the level of the transcripts containing exon 5 diered between tissues, developmental stages and species, whereas splicing of KTS remained constant (Renshaw et al., 1997) .
In model systems a number of genes that can be regulated by WT1 have been identi®ed, including growth factors and growth factor receptors, which may be important targets for the regulation of growth and dierentiation by WT1. Depending on the promoter used WT1 can act as an activator or a potent repressor of genes (for a review see Reddy and Licht, 1996) . Several transcription factors activate in one circumstance and repress in another. For example the Drosophila KruÈ ppel protein converts from an activator to a repressor in a concentrationdependent manner. At low concentration in a monomeric form it activates transcription and at higher concentrations homodimers are formed that act as repressors (Sauer and JaÈ ckle, 1993) . It has been shown that amino acids at the amino terminus are responsible for homodimerization of the WT1 protein (Moet et al., 1995) . A search for interaction partners led to the description of p53 as a possible target protein, whose function is altered through direct interaction with WT1 (Maheswaran et al., 1995) . Using yeast two hybrid assays WT1 interacting proteins were identi®ed as WT1 itself (Reddy et al., 1995; Moet et al., 1995) , human ubiquitin-conjugating enzyme 9 and the prostate apoptosis response gene, Par4 (Johnstone et al., 1996) . Recently it was shown that the DNA binding activity of WT1 may be regulated by phosphorylation (Ye et al., 1996; Sakamoto et al., 1997) . The function of the WT1 protein may thus be modulated in a number of dierent ways, including alternative splicing, phosphorylation and dimerization. However it is currently not precisely known whether WT1 is present in vivo as a monomer, homo-and/or heterodimer, which isoforms associate and whether the association is developmentally regulated. Meaningful functional studies of the WT1 protein can only be performed when it is known in which con®guration the protein exists in vivo. In order to begin to address these questions we started to isolate the WT1 protein from its native source and determined whether it is present as a monomer, dimer or higher order complex and which WT1 isoforms are found in these complexes.
For that purpose we prepared nuclear extracts from frozen fetal and adult kidney tissue and three Wilms' tumor specimens without mutations at the WT1 locus (Schumacher et al., 1997) . To determine the size of WT1, native proteins were size separated by gel ®ltration on superdex 200 HR by FPLC. Fractions were resolved on SDS-gradient gels, transferred to nitrocellulose and analysed in Western blots using the C19 WT1 antibody (Santa Cruz). Transfection of WT1 constructs +17aa into COS cells revealed that WT1 isoforms containing the 17 amino acid insertion (WT1+17aa) migrate with a molecular weight of 54 kDa and the form lacking these (WT1-17aa) with 52 kDa (data not shown).
Size fractionation by gel ®ltration of a nuclear extract from fetal kidney revealed that WT1 elutes at 80 kDa (Figure 1a) . Only the WT1-17aa isoform is detectable in 14 week old fetal kidney (see Figure 1b) . In contrast in adult kidney the majority of WT1 elutes at a size of approximately 120 kDa, containing both WT1 isoforms, with a higher abundance of the +17aa isoform (Figure 1a and b) . In addition some of the WT1 protein eluted in the¯ow through fractions (Figure 1a) . The exclusion size of the gel matrix is 700 kDa, suggesting that a minor fraction of WT1 is present in a complex of at least 700 kDa, containing mostly the +17aa isoform (Figure 1a and b) . Two tumor derived nuclear extracts exhibited elution patterns resembling that of adult kidney but with relatively more WT1 protein in the complex of Figure 1 (a) WT1 elution pattern from fetal and adult kidney and three Wilms' tumors. Nuclear extracts were prepared from snap frozen tissues as described by Dignam et al. (1983) , aliquoted and frozen before further use. The WT1 protein concentration was determined by Western blot analysis. Before loading the gel®ltration column, all protein extracts were spun at 130 000 g to remove aggregates. 1.5 ± 2.5 mg nuclear extract in 20 mM HEPES pH 7.9 was loaded on a Superdex 200 HR 10/30 column (Pharmacia). The running buer for gel ®ltration contained 20 mM HEPES pH 7.9, 10% glycerol, 200 mM NaCl 2 , 0.4 mM PMSF and 1 mM DTT. Each chromatography run was followed by a calibration run with a mix of the following proteins: apoferritin, 440 kDa, IgG, 150 kDa and BSA, 67 kDa. Twenty fractions were collected and the molecular weight of the marker proteins was determined after separation on 12% PAGE-gels and Coomassie staining. For detection of WT1, fractions were tested using the polyclonal rabbit WT1 antibody C19 (Santa Cruz). Sizes are indicated above the blots. In the case of tumor 3 fractions 9 and 10 corresponding to a size of 320 kDa were rechromatographed and after the second run, WT1 eluted at 120 kDa. approximately 700 kDa. Both splice variants +17aa are seen in this complex, with a higher abundance of the +17aa isoform. Equal amounts of WT1 elutes at 120 kDa and in the tumors only the WT1-17aa isoform is found in this complex (Figure 1a) . In unseparated nuclear extracts from these tumors both isoforms are seen, with a higher abundance of WT1+17aa (data not shown).
In a third tumor a dierent elution pattern of WT1 was found with the majority eluting at approximately 320 kDa. Both WT1 +17aa isoforms with a higher abundance of the 717aa are seen in this complex (Figure 1a) . In addition WT1 elutes at 80 ± 90 kDa containing only the 717aa form, similar to the complex seen in fetal kidneys. To investigate, if the elution of WT1 at 320 kDa is due to bound DNA or RNA, we treated fractions 9 and 10 with nuclease and rechromatographed these. The 320 kDa complex was disrupted through this second round of chromatography even in the absence of nuclease and WT1 eluted at the size previously seen in other tissues of 120 kDa (Figure 1a) , suggesting that the 320 kD complex represents an unstable protein association.
To study whether WT1 has an intrinsic property to form complexes we renatured whole-cell extracts prepared from another Wilms' tumor with the guanidinium isothiocyanate method. In this method proteins are denatured during isolation and any covalent protein interactions should be disrupted. After renaturation the proteins were size separated using sucrose gradient centrifugation as a faster method. Fractions were tested for WT1 through Western blotting and most of WT1 was again detected in fractions of 120 kDa con®rming the results obtained with native extracts in size exclusion chromatography (data not shown). This experiment suggests, that the ability to form a complex of 120 kDa is an intrinsic property of WT1. A summary of the results obtained in this study is shown in Table 1 .
Discussion
In this study we show that native WT1 protein, isolated from frozen human kidney and Wilms' tumors, is found in complexes of 80 kDa, 120 kDa, 320 kDa and over 700 kDa. The 80 kDa and 120 kDa complexes from fetal kidney and Wilms' tumors contain mostly the 717aa splice form, whereas in adult kidney the +17aa form is also found in the 120 kDa complex. It is interesting to note, that only in the non-proliferating tissue (adult kidney) the 120 kDa complex contains more of the +17aa isoform, which was shown to have the strongest transcriptional and growth suppressive properties (Reddy et al., 1995; Wang et al., 1996) . This is in agreement with gel®ltration of lysates of BRK-cells transfected with human WT1, where the majority of WT1 eluted at 100 ± 150 kD and a minor fraction at the size of the monomeric form (Maheswaran et al., 1993) .
The complex of 80 ± 90 kDa was only seen in fetal kidney and in one tumor. The size of this complex suggests that WT1 is complexed with a protein of approximately 30 ± 40 kDa. The 120 kDa complex found in adult kidney and in three Wilms' tumor samples may contain homodimers of WT1 or a heterodimer consisting of WT1 and another protein of approximately 55 kDa, like p53. However by Western blotting p53 was only detected in one tumor (tumor 1) and in this case the 120 kDa fractions were also positive for p53. Because only limiting amounts of proteins were present after chromatography it was not possible to demonstrate a physical association using coimmunoprecipitation. The other tumors did not contain p53 by Western blotting but WT1 was also found at a size of 120 kDa, suggesting that at least in these cases p53 is not a normal component of this complex.
In the 14 week-old fetal kidney studied here WT1 717aa is the most abundant isoform which was also observed by Grubb et al. (1994) . It has been reported that during mouse kidney development and in Wilms' tumors the relative ratio of mRNA transcripts of the four isoforms remains constant with a ratio of 2 : 1 for the presence/absence of exon 5 (Rupprecht et al., 1994; Haber et al., 1991) . However our own data (Brenner et al., 1992) and those of Renshaw et al. (1997) show that the ratios dier between tumors and tissues during development. We found both WT1 isoforms but with a higher abundance of +17aa in 24 week old fetal kidney and in adult kidney (V Schumacher and BRP, unpublished observation). Renshaw et al. (1997) also found that in adult kidney the WT1 +17aa isoform is the most abundant, whereas in fetal kidney (no age given) both forms are present with less of the +17aa, suggesting that during development a switch from WT1 717aa to WT1+17aa seems to occur.
We have shown here that native WT1 protein from Wilms' tumors and adult kidney is found in a 120 kDa complex. In contrast in fetal kidney a complex of 80 kDa is seen and homodimerization of WT1 may be prevented by complexing with another protein. Scaling up this approach will help to biochemically identify the The isoforms identi®ed in the complexes are indicated. *Due to the low amount of WT1 protein in this large complex in adult kidney it was not possible to determine whether small amounts of the 717aa isoform was also present proteins that associate with WT1 during kidney development and in Wilms' tumors.
